Recently, blood pressure medication recalls have involved over a million bottles and affected the same number of people prescribed medicine used to treat high blood pressure. The Food and Drug Administration (FDA) has issued dozens of blood pressure medicine recalls, highlighting concerns for contaminants, negligent manufacturing processes, and mix-ups. Many involve nitrosamine impurities, chemicals that the FDA classifies as high cancer risks for humans.
Nitrosamine impurities form during the manufacturing process, and this contamination went undetected for years.
The product liability attorneys at Reich & Binstock have been monitoring these closely. We represent consumers who developed cancer or suffered serious adverse health consequences after taking medication to lower blood pressure.
This page offers a comprehensive, regularly updated list of blood pressure medications recalled, what to do if a prescription used to treat high blood pressure is in your cabinet, and how to file claims if you’ve already suffered harm.
For a free consultation, call 713-622-7271 or fill out our contact form. We handle all cases on a contingency fee basis, so you don’t owe anything unless we win.
Blood Pressure Medication Recall List
- Valsartan
- Losartan
- Irbesartan
- Amlodipine Olmesartan
- Quinapril
- Lisinopril With Hydrochlorothiazide
- Metoprolol
- Carvedilol
- Nebivolol
- Ziac
- Prazosin Hydrochloride
Blood Pressure Medications Recalled – 2026
There have been over a million bottles of both brand-name and generic blood pressure medicines recalled by the FDA’s Center for Drug Evaluation in the past few years. Below is a list of the most recent blood pressure medications recalled in 2026:
Baxter / Welch Allyn Blood Pressure Cuff Recall – Voluntary Recall for Latex and Allergy Risk
Baxter International issued a voluntary recall affecting certain reusable blood pressure cuffs manufactured under the Welch Allyn brand. The cuffs were incorrectly labeled as “not made with natural rubber latex,” even though they contained a latex rubber band component. For patients and healthcare workers with latex allergies, exposure poses serious allergy risks. This affects certain cuffs, gauges, and vital signs monitors used in hospitals, clinics, and home healthcare settings.
Glenmark Ziac Recall
In November 2025, Glenmark Pharmaceuticals issued a voluntary recall of around 11,136 bottles of bisoprolol fumarate and hydrochlorothiazide tablets, after testing of reserve samples revealed that trace amounts of ezetimibe (brand name, Zetia, prescribed to lower high cholesterol) had contaminated blood pressure drugs during manufacturing.
The FDA classified the Ziac recall as a Class III risk level. This suggests that exposure to a violative product isn’t likely to cause serious adverse health consequences. The Glenmark Ziac recall covered 30-count, 100-count, and 500-count bottles in 2.5mg/6.25mg and 5mg/6.25mg doses, with November 2025 to May 2026 expiration dates.
This comes after an FDA warning letter to Glenmark Pharmaceuticals.
Teva Pharmaceuticals Prazosin Recall
Prazosin is an alpha-blocker prescribed to treat high blood pressure. It is also widely prescribed off-label to manage post-traumatic stress disorder (PTSD) symptoms, increase urination, relax blood vessels, and increase blood flow.
In October 2025, Teva Pharmaceuticals and distributor Amerisource Health Services initiated a voluntary recall of over 580,000 bottles of prazosin hydrochloride capsules. This covered 1 mg, 2 mg, and 5 mg capsule strengths from expiration dates ranging from October 2025 through February 2028.
The Teva Pharmaceuticals prazosin recall was triggered after researchers detected high levels of N-nitroso prazosin, a potential cancer-causing nitrosamine impurity that can form from a chemical reaction during production.
The FDA classified this as Class II. This means the medicine could cause temporary or reversible but serious adverse health consequences.
Medline Blood Pressure Monitor Recall
Medline Industries recalled blood pressure monitors for faulty microchips that could cause them to fail to power on, display inaccurate values, or overheat. For patients relying on Medline’s monitors to manage hypertension, an inaccurate reading could lead to a heart attack or dangerous prescription adjustments based on inaccurate data.
Here are the Medline units affected:
Product | UDI / DI | Lot Numbers |
|---|---|---|
MDS4001 | 100888277361228 | 230280001, 230380001, 230680001, 230780001, 230880001 |
MDS4001LA | 100884389106955 | 230480003, 230780003, 231180003 |
MDS4001PLUS | 100888277362089 | 230280004, 230480004, 230780004, 231080004 |
FDA Safety Communication for Unauthorized BP Devices
The FDA issued a broader safety communication with the following warnings:
WHOOP “Blood Pressure Insights” (BPI)
The Food and Drug Administration issued a warning letter to WHOOP, Inc. According to the FDA, WHOOP marketed BPI as capable of providing blood pressure-related data without FDA oversight. For patients relying on WHOOP’s BPI to manage hypertension, an inaccurate reading can lead to a heart attack or other cardiovascular risk.
Wearable Smartwatch And Smart Ring Alleging to Notify About High Blood Pressure
The Food and Drug Administration has warned that several smartwatches and smart rings falsely claim to detect or alert users about high blood pressure. These devices haven’t undergone FDA-required testing, and their readings don’t accurately reflect blood pressure levels. The agency advises users to consult their doctors before relying on any wearable technology to manage lower blood pressure or hypertension.
ARB Blood Pressure Medication Recalls
ARBs are the most widely prescribed medications to treat high blood pressure in the U.S. In July 2018, the FDA issued numerous ARB blood pressure medication recalls due to nitrosamine impurities that persisted for years before being identified. These chemicals include NDMA, NDEA, and NMBA. The FDA classifies the chemicals as having increased cancer risk with prolonged exposure. The ARB blood pressure medication recall is the largest and most consequential in U.S. history, covering several drug products.
Valsartan Recall
- Brand name: Diovan
- Drug class: Angiotensin II Receptor Blocker (ARB)
Valsartan was the first ARB blood pressure medication recalled for nitrosamine impurities. In July 2018, the FDA announced that some generic valsartan products manufactured by Zhejiang Huahai Pharmaceutical contained NDMA. The nitrosamine impurities formed when the company changed its manufacturing process in 2012.
This means that patients consumed contaminated valsartan daily for as long as 6 years before the problem was found.
Multiple batches also included NDEA, a probable human carcinogen,
Patients who took generic valsartan and were diagnosed with cancer may be eligible to file claims. Here is the Valsartan blood pressure medication recall list:
Name | Drug Name | MG | NDC | Lot | Expiry |
|---|---|---|---|---|---|
Camber | Valsartan | all | all | All lots | 7/18-6/20 |
Mylan | Valsartan | all | all | All lots | 11/18–8/20 |
Teva/Actavis | Valsartan, Valsartan-HCTZ, Amlodipine/Valsartan, Amlodipine/Valsartan/HCTZ | all | all | all lots | 9/18–8/20 |
Torrent | Valsartan, Amlodipine/Valsartan, Amlodipine/Valsartan/HCTZ | all | all | all | 7/19–10/20 |
Solco Healthcare | Valsartan, Valsartan-HCTZ | all | all | all lots | 7/18–1/20 |
Major Pharmaceuticals | Valsartan Tablets | 80, 160 | all | all lots | 7/18–5/19 |
Aurobindo | Amlodipine/Valsartan | 5/160 | 65862-737-30 | VESA17013-A, VESA17014-A, VESA18001-A, VESA18002-A | 10/19, 12/19 |
|
| 10/160 | 65862-739-30 | VFSA17008-A, VFSA17009-A, VFSA17010-A, VFSA18002-A, VFSA18003-A, VFSA18007-A, VFSA18008-A | 10/19–3/20 |
|
| 10/320 | 65862-740-30 | VKSA17008-A, VKSA17014-A, VKSA17015-A, VKSA17016-A, VKSA17017-A, VKSA18001-A, VKSA18002-A, VKSA18004-A, VKSA18005-A | 5/19–3/20 |
|
| 5/320 | 65862-738-30 | VMSA17012-A, VMSA17013-A, VMSA17014-A, VMSA17015-A, VMSA17016-A, VMSA17017-A | 11/19 |
| Valsartan/ Hydrochlorothiazide Tablets | 320/12.5 | 65862-550-90 | HRSA17033-A, HRSA17034-A, HRSA17035-A, HRSA17036-A, HRSA17037-A | 10/20 |
|
| 160/12.5 | 65862-548-90 | HTSA17033-A, HTSA17034-A, HTSA17035-A, HTSA17036-A, HTSA17037-A, HTSA17040-A, HTSA17041-A, HTSA17042-A, HTSA17043-A | 10/20–11/20 |
|
| 320/25 | 65862-551-90 | HTSB17049-A, HTSB17054-A, HTSB17055-A, HTSB17056-A, HTSB17057-A, HTSB17058-A, HTSB17059-A, HTSB17060-A, HTSB17062-A, HTSB17063-A, HTSB17064-A, HTSB17065-A, HTSB17066-A, HTSB17067-A, HTSB17068-A, HTSB17069-A, HTSB18001-A, HTSB18002-A, HTSB18003-A, HTSB18004-A, HTSB18005-A, HTSB18006-A, HTSB18007-A | 8/20–12/20 |
|
| 80/12.5 | 65862-547-90 | HVSA17011-A, HVSA17012-A, HVSA18001-A | 11/20–12/20 |
|
| 160/25 | 65862-549-90 | HVSB17023-A, HVSB17036-A, HVSB17037-A, HVSB17038-A, HVSB17039-A, HVSB17040-B, HVSB18001-A, HVSB18002-A, HVSB18003-A, HVSB18004-A | 8/20–12/20 |
Losartan Recall
- Brand name: Cozaar
- Drug class: ARB
- Reason: NDEA and NMBA
In October 2018, the FDA announced that some batches of generic losartan products contained nitrosamine impurities involving NDEA and NMBA, both of which pose cancer risks. Generic versions of Hyzaar, losartan hydrochlorothiazide, were included in the blood pressure medication recall for the same nitrosamine impurities in losartan.
Brand / Company | Drug Name | MG | NDC | Lot Numbers | Expiry Dates |
|---|---|---|---|---|---|
Camber | Losartan | 25 | 31722‑700‑10 | LOP18038, LOP18039, LOP18057 | 12/19, 01/20 |
Camber | Losartan | 50 | 31722‑701‑30 | LOP17028C, LOP17064A | 09/19, 11/19 |
Camber | Losartan | 50 | 31722‑701‑90 | LOP17027, LOP17063, LOP17093, LOP17094, LOP17095, LOP17097A, LOP17105, LOP17107 | 09/19–12/19 |
Camber | Losartan | 50 | 31722‑701‑10 | LOP17004, LOP17028B, LOP17048, LOP17049, LOP17056, LOP17073, LOP17074, LOP17076, LOP17096, LOP18077A, LOP18078, LOP18079, LOP18080, LOP18081, LOP18084, LOP18095, LOP18096 | 09/19–03/20 |
Camber | Losartan | 100 | 31722‑702‑30 | LOP17011, LOP17087 | 08/19, 11/19 |
Camber | Losartan | 100 | 31722‑702‑90 | LOP17012, LOP17013, LOP17042, LOP17043, LOP17044, LOP17045, LOP18024, LOP18025, LOP18026, LOP18027, LOP18028, LOP18029, LOP18030 | 08/19–12/19 |
Camber | Losartan | 100 | 31722‑702‑10 | LOP17005, LOP17014, LOP17016, LOP17023, LOP17083, LOP17084, LOP17085, LOP17086, LOP18021, LOP18022, LOP18023, LOP18126, LOP18127, LOP18128, LOP18129, LOP18130, LOP18131C, LOP18133 | 05/19–06/20 |
Golden State Medical Supply | Losartan | 25 | 60429‑316‑10 / ‑30 / ‑90 | GS014817, GS015172, GS015204, GS017045, GS017276, GS017341, GS018318, GS017342, GS017808 | 06/19, 02/20 |
Golden State Medical Supply | Losartan | 50 | 60429‑317‑10 / ‑90 | GS017387, GS017651, GS017479 | 01/20 |
Golden State Medical Supply | Losartan | 100 | 60429‑318‑10 / ‑90 | GS014045, GS014305, GS014054, GS014044, GS016338, GS016341, GS016342, GS016343, GS016344, GS016345, GS016535, GS016524, GS016539, GS016969, GS016973, GS017337, GS017384, GS017385, GS017539, GS017540, GS017542, GS017543, GS018524, GS017984, GS017985, GS017986, GS018263, GS018264, GS018265, GS017042, GS017043, GS017044, GS017541 | 01/19–02/20 |
H J Harkins / Pharma Pac | Losartan | 100 | 76519‑1033‑03 | LTO00EW | 11/19 |
H J Harkins / Pharma Pac | Losartan | 100 | 31722‑0702‑30 | LOP17087 | 11/19 |
Heritage | Losartan | 25 | 23155‑644‑09 | CLO17006A | 11/19 |
Heritage | Losartan | 50 | 23155‑645‑09 | CLO17007A, CLO17008A, CLO17009A, CLO17009B, CLO17010A | 11/19 |
Heritage | Losartan | 50 | 23155‑646‑10 | CLO18023A | 04/20 |
Heritage | Losartan | 100 | 23155‑646‑09 | CLO17012A, CLO17013A, CLO17014A, CLO17015A, CLO17016A, CLO17017A, CLO18001A, CLO18002A, CLO18002B, CLO18020A, CLO18021A, CLO18022A | 11/19–04/20 |
Legacy (Hetero/Camber) | Losartan | 25 | 68645‑577‑54 | 180952, 180953, 181086, 181572 | 09/19–01/20 |
Legacy (Hetero/Camber) | Losartan | 50 | 68645‑578‑54 | 180921, 180922, 180923, 180924, 181118, 181119, 181407, 181408, 181573, 181725, 181726, 181948, 181960, 182385, 182386, 182387 | 09/19–03/20 |
Torrent | Losartan | 50 | 13668‑409‑10 / ‑30 / ‑90 | 4DU2E044, BDK2E001, BDK2E012, BDK2E013, 4L67C035, 4DU2D077, 4DU2D087, 4DU2E023, 4DU2E009 | 02/20–10/19 |
Torrent | Losartan | 100 | 13668‑115‑10 / ‑30 / ‑90 | BO31C016, 4DU3E016, 4DU3E017, 4DU3E019, 4DU3C012, 4DU3C015, 4DU3C040, 4DU3E049, 4DU3E050, 4DU3E009, 4DU3D018, 4DU3E062, 4DU3E063, 4DU3E065 | 04/19–11/21 |
Torrent | Losartan/HCTZ | 50/12.5 | 13668‑116‑10 / ‑30 / ‑90 | BP02D005, BP02C051, BP02C052, BEF7E004, BEF7D006, BEF7D017, BEF7D010, BEF7D011 | 10/19–06/20 |
Torrent | Losartan/HCTZ | 100/12.5 | 13668‑117‑90 | BX35D024, BEF8D060, BEF8D061, BEF8D062, BEF8D063, BEF8D064 | 11/20–01/20 |
Torrent | Losartan/HCTZ | 100/25 | 13668‑118‑10 / ‑30 / ‑90 | BX35C020, BX35C049, BX35C022, BX35C023, BEF8D058, BEF8D023, BEF8D024, BEF8D025, BEF8D021, BEF8D022, BEF6D038, BEF6D030, BEF6D047, BEF6D048, BEF6D049, BEF6E009, BEF6E010, BEF6E011, BEF6E012, BP04D012, BP04D013, BP04C092, BEF6E005, BEF6E006, BP04D016, BP04D017, BP04D018 | 01/19–12/20 |
Irbesartan Recall
- Brand name: Avapro
- Drug class: ARB
Irbesartan was the third major ARB blood pressure medication recall. The Food and Drug Administration updated the data multiple times as additional information for new contaminated batches was found.
Company | Drug Name | MG | NDC | Lot Numbers | Expiry Dates |
|---|---|---|---|---|---|
Lupin | Irbesartan | 75 | 68180‑410‑06 | H000843, H805727, H901579 | 11/21, 03/22, 02/23 |
| Irbesartan | 75 | 68180‑410‑09 | H000844, H000964, H804311, H805267, H805268, H805269, H805725, H805726, H901497, H901577, H901578, H902258 | 08/21, 11/21, 01/22, 03/22, 02/23, 03/23 |
| Irbesartan | 150 | 68180‑411‑09 | H805643, H901581, H902139, H902140 | 11/21, 04/22 |
| Irbesartan | 300 | 68180‑412‑06 | H804310, H900050, H902262 | 08/21, 11/21, 05/22 |
| Irbesartan | 300 | 68180‑412‑09 | H000845, H000846, H000965, H805345, H805346, H805347, H805724, H900061, H900062, H900445, H901489, H901490, H901491, H902261 | 11/21, 12/21, 01/22, 03/22, 02/23, 03/23, 05/22 |
| Irbesartan / HCTZ | 150/12.5 | 68180‑413‑06 | H804537, H805148, H900063, H900522, H901582 | 09/21, 10/21, 12/21, 01/22, 04/22 |
| Irbesartan / HCTZ | 150/12.5 | 68180‑413‑09 | H000963, H804507, H804536, H805070, H805149, H900064, H900523, H901583, H902530 | 09/21, 10/21, 12/21, 01/22, 03/23, 04/22 |
| Irbesartan / HCTZ | 300/12.5 | 68180‑414‑06 | H804192, H805348, H900065, H902264 | 08/21, 11/21, 12/21, 05/22 |
| Irbesartan / HCTZ | 300/12.5 | 68180‑414‑09 | H804082, H804121, H804338, H804538, H804539, H805349, H805350, H900066, H900067, H902265, H902275, H902276, H902531, H902532 | 08/21, 09/21, 11/21, 12/21, 04/22, 05/22 |
Prinston, dba Solco | Irbesartan | 300 | 43547‑376‑09 | 331B18009 | 02/21 |
| Irbesartan / HCTZ | 150/12.5 | 43547‑330‑03 | 325D18004, 325D18005 | 03/21 |
| Irbesartan / HCTZ | 150/12.5 | 43547‑330‑09 | 325B18004 | 03/21 |
| Irbesartan / HCTZ | 300/12.5 | 43547‑331‑03 | 327A18001, 327A18002 | 03/21 |
| Irbesartan / HCTZ | 300/12.5 | 43547‑331‑09 | 327B18008, 327B18009 | 03/21 |
ScieGen / GSMS Inc. | Irbesartan | 150 | 60429‑641‑90 | B161003, B161004, B161006, B161007, B161008, B161009, B161010, C161001, C161003 | 09/19, 11/19, 02/20, 05/20 |
| Irbesartan | 300 | 60429‑642‑30 | GS019036, GS019073, GS021472, GS021530, GS022234 | 09/19, 11/19, 02/20 |
| Irbesartan | 300 | 60429‑642‑90 | B162009, B162010, B162011, B162012, B162013, B162014, B162015, C162001 | 09/19, 11/19, 02/20 |
ScieGen / Westminster | Irbesartan | 75 | 69367‑119‑01 | B160002A, B160002B | 09/19 |
| Irbesartan | 150 | 69367‑120‑01 | B161005A, C161002A | 09/19, 02/20 |
| Irbesartan | 150 | 69367‑120‑03 | B161005B, C161002B | 09/19, 02/20 |
| Irbesartan | 300 | 69367‑121‑01 | B162008A, C162002A | 09/19, 02/20 |
| Irbesartan | 300 | 69367‑121‑03 | B162008B, C162002B | 09/19, 02/20 |
Amlodipine Olmesartan Recall
- Brand name: Azor
- Drug class: Calcium channel blocker + ARB
In August 2025, Ascend Laboratories issued a voluntary recall for amlodipine and olmesartan medoxomil. The blood pressure medication recall included 8,568 bottles that failed to meet dissolution specifications. When pills for treating high blood pressure don’t dissolve properly, active ingredients don’t release at the expected rate. This is a Class II risk.
ACE Inhibitor Blood Pressure Medication Recall
ACE (angiotensin-converting enzyme) inhibitors are another class of medications widely used to treat high blood pressure.
Quinapril Recall
- Brand name: Accupril
- Drug class: ACE Inhibitor
- Date: December 2022
- Doses: 20mg and 40mg tablets
Lupin Pharmaceuticals issued a voluntary recall of quinapril for the presence of nitrosamine impurities at high levels. Like the nitrosamine impurities found in ARBs, the recalled quinapril is considered a potential human carcinogen.
Lisinopril With Hydrochlorothiazide Recall
- Brand name: Zestoretic (generics)
- Drug class: ACE Inhibitor + diuretic
Lupin Pharmaceuticals voluntarily recalled nearly 59,000 bottles of lisinopril and hydrochlorothiazide tablets in July 2025 after a patient reported a sealed bottle contained a foreign tablet. This was later confirmed to be an HIV-1 medication that was mixed in the Nagpur, India, facility.
This is a Class II risk with the cause described as a “Product Mix Up.”
The reported lot (QA01081) affects 100-count bottles with an expiration date of April 2027.
If patients take an HIV medication, they miss a critical dose of hypertension treatment.
Quinapril and Hydrochlorothiazide Recall (Accuretic)
- Brand name: Accuretic
- Drug class: ACE Inhibitor + diuretic
In March 2022, Pfizer voluntarily recalled several batches of Accuretic and its generics due to the presence of a nitrosamine. In October 2022, Aurobindo Pharma USA also issued a Quinapril and Hydrochlorothiazide recall.
Manufacturer | Product | Expiration Date Range | Lots |
|---|---|---|---|
Pfizer (Accuretic) | Quinapril HCl/HCTZ | 4/22 -8/24 |
|
Greenstone (Generic) | Quinapril – HCTZ; Quinapril HCl/HCTZ generics | 2/23-3/23 |
|
Aurobindo (Generic) | Quinapril and Hydrochlorothiazide | 1/23 | QE2021005-A, QE2021010-A |
Beta Blocker Blood Pressure Medication Recall
There have been a series of major beta-blocker recalls in 2025.
Metoprolol Succinate Recall (Toprol)
- Brand name: Toprol-XL
- Manufacturers: Granules Pharmaceuticals, Teva Pharmaceuticals
In 2026, Teva Pharmaceuticals recalled over 112,000 bottles of Metoprolol Succinate XR tablets:
Strength | Count | NDC | Lot Number | Expiration |
|---|---|---|---|---|
25 mg | 100 | 45963-709-11 | 0715J251, 0716J251, 0717J251 | 12/26 – 1/27 |
25 mg | 1,000 | 45963-709-96 | 0715J252, 0716J252, 0717J252 | 12/26 – 1/27 |
50 mg | 100 | 45963-676-11 | 0486G251, 0487G251, 0488G251 | 1/27 |
50 mg | 1,000 | 45963-676-96 | 0486G252, 0487G253, 0488G252 | 1/27 |
100 mg | 100 | 45963-677-11 | 0718J251, 0729J251, 0730J251 | 12/26 |
100 mg | 1,000 | 45963-677-96 | 0718J252, 0729J252, 0730J252 | 12/26 |
200 mg | 100 | 45963-678-11 | 0686H251, 0687H251, 10688H251 | 2/27 |
In June 2025, Granules Pharmaceuticals recalled more than 33,000 bottles of 25mg Metoprolol Succinate XR in 100-count and 500-count bottles due to dissolution problems. Batch numbers include: #1400008A and #1400008B
Metoprolol Tartrate Recall
There was a Westminster metoprolo tartrate recall for specific bottles contaminated with nitrosamine.
- Expiration: 9/25-7/26
- Strength: 50 mg and 100 mg
- Count: 1,000
A separate TruPharma/Rubicon Research metoprolol tartrate recall occurred in May 2025 because metal was found embedded in a tablet.
- Lot: 231037H1
- Expiration: 06/27
- Strength: 25mg
- Count: 1,000
Carvedilol Recall
- Brand name: Coreg
- Manufacturers: Glenmark Pharmaceuticals, Harvard Drug Group/Major Pharmaceuticals, RemedyRepack
In January 2025, Glenmark began a series of voluntary recalls after discovering high levels of N-Nitroso Carvedilol Impurity-1 (NNCI-I) in certain batches. Glenmark has experienced repeated quality control failures. This event was at least the fifth instance within 12 months in which Glenmark was forced to recall medications due to nitrosamine.
Additionally, because they repackage Glenmark’s products, Major Pharmaceuticals and RemedyRepack also list separate recalls not included here.
Strength | Count | NDC | Lot Number | Expiration |
|---|---|---|---|---|
3.125 mg | 100 | 68462-162-01 | 19231450, 19233345, 19234275, 19240280 | 3/25-12/25 |
3.125 mg | 500 | 68462-162-05 | 19231450, 19231464, 19231471, 19231493, 19232083, 19232103, 19232658, 19233328, 19233343, 19233344, 19233345, 19234275, 19240280, 19234843, 19235039, 19240296 | 3/25-12/25 |
6.25 mg | 100 | 68462-163-01 | 19231618, 19232064, 19232324, 19233369, 19234162, 19240543 | 3/25-1/26 |
6.25 mg | 500 | 68462-163-05 | 19231174, 19231199, 19231517, 19231527, 19231566, 19231568, 19231595, 19231618, 19231634, 19231638, 19232043, 19232051, 19232064, 19232322, 19232324, 19232365, 19232380, 19232389, 19232736, 19232743, 19232746, 19232756, 19232757, 19233369, 19233371, 19233405, 19233416, 19234162, 19234183, 19234192, 19234204, 19234223, 19234243, 19234263, 19240223, 19240543, 19231448, 19231164, 19234165, 19234242, 19234743, 19234774, 19234993, 19240203, 19240211, 19240214, 19240247, 19240249, 19240272, 19240319 | 2/25-1/26 |
12.5 mg | 500 | 68462-164-05 | 19231899, 19231922, 19231927, 19231967, 19231979, 19232226, 19232234, 19232265, 19232271, 19232758, 19232759, 19232762, 19232788 | 4/25-6/25 |
25 mg | 500 | 68462-165-05 | 19231107, 19231114, 19231152, 19234866 |
Nebivolol Recall
- Brand name: Bystolic
- Manufacturer: Glenmark Pharmaceuticals and Aurobindo Pharma
The December 2024 Aurobindo Nebivolol recall involved several batches of 2.5 mg tablets due to high levels of a nitrosamine impurity.
- Expiration: 4/27
- Strength: 2.5 mg tablets (30-count bottles)
The November 2025 Glenmarkk nebivolol recall was due to cross-contamination with other products. This also included products distributed by AvKARE.
- Expiration: 5/26
- Strength: 20 mg (90-count bottles)
Ziac Recall – Class III (Bisoprolol/Hydrochlorothiazide)
- Drug class: Beta-blocker + diuretic
- Reason: Cross-contamination with ezetimibe (cholesterol drug)
- Scope: 11,100 bottles
- Classification: Class III (low risk)
The Ziac recall is discussed above.
Alpha Blocker Blood Pressure Medication Recall
Prazosin Hydrochloride Capsules Recall
- Brand name: Minipress
- Recall reason: N-nitroso Prazosin impurity above acceptable limits
- Recall date: October 2025
- Manufacturer: Teva Pharmaceuticals
- Scope: 580,000+ capsules (1mg, 2mg, 5mg doses)
Patients can identify whether their prazosin came from Teva by checking the prescription label for the abbreviations “MFG Teva” or “MFR Teva.” The first four digits of the National Drug Code (NDC) on Teva products will show “0093.”
The Prazosin Hydrochloride recall is discussed above.
How to Check If Your Medication Was Recalled
If you’re concerned that a medicine you take to lower blood pressure was included in the Food and Drug Administration (FDA) recall, you can take the following steps to determine if the medication you were prescribed was affected:
Check the prescription label for the manufacturer’s name. Look for the “MFG” or “MFR” on the pharmacy label. Common companies involved in blood pressure medication recalls include Teva, Glenmark, Lupin, Westminster, Torrent, Hetero/Camber, Mylan, and Aurobindo.
Compare the lot number against the FDA recall lists. Every medication bottle is printed with a lot number and expiration date. The FDA maintains a searchable recall database where specific lot numbers can be checked against active recall notices.
Contact your pharmacy. Pharmacists have access to the Food and Drug Administration databases and can determine whether your medication was affected. Many pharmacists proactively notify patients who are taking recalled blood pressure medications.
Use the FDA’s searchable enforcement reports. The Food and Drug Administration publishes weekly reports that list all active drug recalls.
Do NOT stop taking blood pressure medication without consulting a doctor or pharmacist. Any medicine prescribed to treat high blood pressure cannot be stopped immediately. Risks include dangerously high blood pressure, increased risk of heart attack, stroke, and rebound hypertension.
Blood Pressure Medication Recalled? Steps For Filing Drug Product Lawsuits
When pharmaceutical companies fail to ensure product safety, patients harmed can seek compensation through product liability lawsuits. Cancer-causing blood pressure medications have been linked to serious adverse health consequences, including cancer risks that changed, and in some cases ended, lives.
Blood Pressure Medication Lawsuits for Nitrosamine Impurities (NDMA, NDEA, NMBA) and Cancer Risk: Valsartan, Losartan, and Irbesartan MDL
The largest blood pressure medication lawsuit in the U.S. involves the contaminated ARB blood pressure medicines: valsartan, losartan, and irbesartan. These cases are consolidated in MDL No. 2875, pending in the U.S. District Court for the District of New Jersey.
Over 1,400 lawsuits have been filed. Plaintiffs allege that pharmaceutical companies Zhejiang Huahai, Hetero Labs, Mylan, Teva, Torrent, and others produced and distributed blood pressure medications contaminated with cancer-causing nitrosamine impurities, and that these companies failed to adequately test their products or warn consumers about the blood pressure medication cancer risks.
The court imposed sanctions against one company for violating discovery orders. As a result, the jury may draw adverse conclusions from the missing evidence. This can potentially significantly favor victims.
Hetero Labs has reached a partial settlement. However, litigation continues against major companies. Losartan settlement negotiations have reached an impasse on certain issues.
Cancer risks that have been linked to nitrosamine-contaminated blood pressure medications include:
- Liver cancer
- Stomach (gastric) cancer
- Colorectal cancer
- Kidney cancer
- Bladder cancer
- Pancreatic cancer
- Esophageal cancer
- Lung cancer
- Prostate cancer
- Non-Hodgkin’s lymphoma
- Multiple myeloma
- Leukemia
Who May Qualify for a Blood Pressure Medication Lawsuit
You may be able to file a lawsuit for a blood pressure medication recall if you meet the following:
- Took a recalled blood pressure medication for six months or longer. This includes generic valsartan, losartan, or irbesartan products manufactured between ~2012-2019 by any of the brands named.
- Received a qualifying cancer diagnosis. The cancer risks must be linked to exposure. Specific cancer types include:
- liver cancer
- stomach cancer
- colorectal cancer
- kidney cancer
- bladder cancer
- pancreatic cancer
- esophageal cancer
- lung cancer
- prostate cancer
- non-Hodgkin’s lymphoma
- multiple myeloma
- leukemia
- Can provide prescription records/medical documentation. You’ll need pharmacy records showing the brand and lot numbers, combined with medical records showing the cancer diagnoses and treatment.
Contact a Texas Lawyer for Blood Pressure Medicine Recall Assistance
Blood pressure medication recalls have spanned several million bottles and injured millions of victims who trusted that the drug products prescribed by their doctors were safe. For those who took these blood pressure medications and suffered serious adverse health consequences, you may be able to seek compensation for medical expenses, lost wages, and other damages.
Reich & Binstock has extensive experience handling pharmaceutical injury and defective drug claims in Texas. We offer free consultations for consumers who believe they were harmed by a dangerous blood pressure medication.
Here is what to do right now:
Check all current blood pressure medications against the Food and Drug Administration’s information provided on this page. Consult a doctor before making any changes.
Time limits apply, so it is important not to delay.
For a free consultation, call 713-622-7271 or fill out our contact form.
